EP4719367A1 - Anticorps anti-ror1 et procédé d'utilisation - Google Patents

Anticorps anti-ror1 et procédé d'utilisation

Info

Publication number
EP4719367A1
EP4719367A1 EP24731897.5A EP24731897A EP4719367A1 EP 4719367 A1 EP4719367 A1 EP 4719367A1 EP 24731897 A EP24731897 A EP 24731897A EP 4719367 A1 EP4719367 A1 EP 4719367A1
Authority
EP
European Patent Office
Prior art keywords
antibody
target
derivative
binding
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24731897.5A
Other languages
German (de)
English (en)
Inventor
Anna KOSTYN
Petrus Johannes Louis Spee
Niina Veitonmaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pure Biologics SA
Original Assignee
Pure Biologics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pure Biologics SA filed Critical Pure Biologics SA
Publication of EP4719367A1 publication Critical patent/EP4719367A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des anticorps se liant à ROR1.
EP24731897.5A 2023-06-05 2024-06-05 Anticorps anti-ror1 et procédé d'utilisation Pending EP4719367A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23177350 2023-06-05
PCT/EP2024/065428 WO2024251787A1 (fr) 2023-06-05 2024-06-05 Anticorps anti-ror1 et procédé d'utilisation

Publications (1)

Publication Number Publication Date
EP4719367A1 true EP4719367A1 (fr) 2026-04-08

Family

ID=86693197

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24731897.5A Pending EP4719367A1 (fr) 2023-06-05 2024-06-05 Anticorps anti-ror1 et procédé d'utilisation

Country Status (5)

Country Link
EP (1) EP4719367A1 (fr)
KR (1) KR20260020428A (fr)
CN (1) CN121240857A (fr)
AU (1) AU2024285667A1 (fr)
WO (1) WO2024251787A1 (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL20C (nl) 1911-06-03 1913-08-01 Krupp Gmbh Verbetering aan geschut met verstelbare dubbelknievormig gebogen rad-as
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
ATE306810T1 (de) 2002-03-05 2005-11-15 Artemis Pharmaceuticals Gmbh Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
GB201003701D0 (en) 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
EP3474854A4 (fr) * 2016-06-27 2020-02-19 The Regents of The University of California Associations médicamenteuses pour le traitement du cancer

Also Published As

Publication number Publication date
KR20260020428A (ko) 2026-02-11
CN121240857A (zh) 2025-12-30
WO2024251787A1 (fr) 2024-12-12
AU2024285667A1 (en) 2026-01-15

Similar Documents

Publication Publication Date Title
US20240076375A1 (en) Anti-TIM-3 Antibodies and Use Thereof
KR102731476B1 (ko) 항-tigit 항체
JP6704954B2 (ja) 親和性成熟抗ｃｃｒ４ヒト化モノクローナル抗体および使用法
JP6983776B2 (ja) グルココルチコイド誘発腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
US10273307B2 (en) Humanized anti-CD134 (OX40) antibodies and uses thereof
CN109475602B (zh) 抗pd-l1和il-2细胞因子
US10604580B2 (en) Combination therapies with anti-CD38 antibodies
KR20200105849A (ko) 항-tigit 항체 및 치료제 및 진단제로서 이의 용도
US20260049143A1 (en) Multispecific antibody with combination therapy for immuno-oncology
CA3043761A1 (fr) Anticorps anti-tim-3 pour combinaison avec des anticorps anti-pd-l1
WO2018115859A1 (fr) Anticorps multispécifique avec polythérapie pour l'immuno-oncologie
JP7550494B2 (ja) 抗ｔｉｇｉｔ抗体およびその用途
KR20210113282A (ko) 항-tigit 항체
TWI677503B (zh) 抗-pd-l1-抗-tim-3雙特異性抗體
WO2024251787A1 (fr) Anticorps anti-ror1 et procédé d'utilisation
WO2024125331A1 (fr) ANTICORPS DIRIGÉS CONTRE SIRPα ET LEURS UTILISATIONS
WO2024251839A1 (fr) Anticorps anti-garp et procédés d'utilisation
KR20260046177A (ko) 항-gprc5d 항체 및 조성물
WO2025113640A1 (fr) Anticorps se liant à lilrb1/2 ou pd1-lilrb1/2 et son utilisation
CN120813377A (zh) Btn3a活化抗体和免疫检查点抑制剂的组合
HK40092523A (zh) 抗ox40抗体、其药物组合物及应用
HK40092523B (zh) 抗ox40抗体、其药物组合物及应用
KR20220049033A (ko) 아르기나제 ii(arg2)에 대한 분자의 결합

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260105

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR